<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002122</url>
  </required_header>
  <id_info>
    <org_study_id>226A</org_study_id>
    <secondary_id>066-174</secondary_id>
    <nct_id>NCT00002122</nct_id>
  </id_info>
  <brief_title>A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients</brief_title>
  <official_title>A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      PRIMARY: To determine the efficacy of azithromycin and rifabutin alone and in combination for&#xD;
      the prevention of disseminated Mycobacterium avium Complex (MAC) infection in HIV-infected&#xD;
      patients. To determine the efficacy of daily versus weekly fluconazole for the prevention of&#xD;
      deep fungal infections in this patient population.&#xD;
&#xD;
      SECONDARY: To determine the incidence of bacterial (including mycobacterial) infections,&#xD;
      cryptosporidiosis, and toxoplasmosis in azithromycin versus non-azithromycin containing&#xD;
      regimens. To determine the incidence of oropharyngeal and vaginal candidiasis in patients&#xD;
      treated with daily versus weekly fluconazole. To compare survival and outcomes of primary&#xD;
      endpoints in the treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive azithromycin alone, rifabutin alone, or the two drugs in&#xD;
      combination for MAC prophylaxis. Patients in each treatment group further receive one of two&#xD;
      doses of concomitant fluconazole for deep fungal prophylaxis, unless specifically excluded&#xD;
      for fluconazole randomization. Patients are followed for 1 to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>720</enrollment>
  <condition>Mycoses</condition>
  <condition>Mycobacterium Avium-Intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Preventive therapy with isoniazid for M. tuberculosis.&#xD;
&#xD;
          -  Maintenance therapy for CMV retinitis.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection or history of an AIDS-defining condition by CDC criteria.&#xD;
&#xD;
          -  One documented CD4 count &lt; 100 cells/mm3 within 12 months prior to study entry.&#xD;
&#xD;
          -  NO active MAC disease, MAC bacteremia, or active mycobacterial infection (tuberculous&#xD;
             or nontuberculous).&#xD;
&#xD;
          -  NO acute opportunistic infection.&#xD;
&#xD;
          -  Life expectancy of more than 6 months.&#xD;
&#xD;
          -  Consent of parent or guardian if less than legal age of consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
        ALL PATIENTS -&#xD;
&#xD;
          -  Unexplained fevers, elevation in alkaline phosphatase, pancytopenia, abnormal liver&#xD;
             function tests, or odynophagia for which the diagnoses of MAC and fungal infections&#xD;
             have not been excluded.&#xD;
&#xD;
          -  Serious hypersensitivity reactions to macrolides or rifampin.&#xD;
&#xD;
          -  Unable to tolerate oral medications. FOR FLUCONAZOLE RANDOMIZATION -&#xD;
&#xD;
          -  Serious hypersensitivity reaction to fluconazole.&#xD;
&#xD;
          -  Active fungal infection (cryptococcosis, histoplasmosis, blastomycosis, aspergillosis,&#xD;
             Candida esophagitis, thrush, vaginal candidiasis).&#xD;
&#xD;
          -  Positive baseline urine cryptococcal culture.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded for fluconazole randomization:&#xD;
&#xD;
          -  Maintenance therapy for deep fungal infections.&#xD;
&#xD;
          -  Chronic therapy with ketoconazole or fluconazole.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Med Ctr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Treatment Ctr / Dept of Medicine and Pediatrics</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med Ctr</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>951282699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Med Ctr</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Havlir DV, Mccutchan JA, Bozzette SA, Dunne M. A double-blind, randomized study of weekly azithromycin, daily rifabutin, and combination azithromycin and rifabutin for the prevention of Mycobactetum avium complex (MAC) in AIDS patients. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:90</citation>
  </reference>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Rifabutin</keyword>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Mycoses</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

